Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Guided Therapeutics ( (GTHP) ) is now available.
On March 2, 2026, Guided Therapeutics, Inc. completed an exchange of certain outstanding warrants issued in a September 1, 2022 private offering, allowing holders to exercise eligible warrants at reduced prices if done by the February 25, 2026 expiration and subject to all-or-nothing exercise conditions within each warrant price tier. The company accepted 4,825,000 warrant shares, representing about 22.7% of eligible warrants, generated $980,000 in cash proceeds, and issued an equal number of restricted common shares, increasing total common shares outstanding from 86,691,976 to 91,516,976 while cancelling the exchanged warrants.
The transaction, conducted under an exemption from Securities Act registration and without payment of commissions, also extended the maturity of remaining unexercised eligible warrants by one year, leaving 16,398,080 such instruments outstanding with staggered expirations between 2026 and 2027. The move enhances Guided Therapeutics’ near-term liquidity, simplifies part of its warrant overhang, and modestly dilutes existing shareholders, while preserving a significant pool of warrants that could provide additional capital if exercised in the future.
More about Guided Therapeutics
Guided Therapeutics, Inc. operates in the medical technology sector, focusing on diagnostic solutions built around its proprietary platforms. The company’s capital structure includes common stock and various classes of warrants, which it actively manages through exchange and exercise programs to support its financing needs and shareholder base.
Average Trading Volume: 21,822
Technical Sentiment Signal: Sell
Current Market Cap: $24.08M
See more data about GTHP stock on TipRanks’ Stock Analysis page.